As the age old saying goes, prevention is better than cure. This is proven by vaccine development which could easily pass for the noblest invention of the recent centuries. Thanks, to inoculation, persistent ailments such as hepatitis, small pox, polio, mumps, measles and mad cow disease are on the verge of extinction. These diseases are no longer a pain to mankind and are no longer considered threats to normal life. Despite it being a decent and life saving development, inoculation still faces a myriad of obstacles.
One of the greatest obstacles to successful launch of immunization as a preventive mechanism against occurrence of diseases in the lack of manufacturing enterprises that are willing to engage in production. Manufacturers in the United States avoid production of vaccines since these medicines are difficult to produce. There is a pressing lack of raw materials, infrastructure and man power used in production of vaccines. Furthermore, manufacturing giants are not interested in producing preventive medicines that extinguish diseases. The manufacturers prefer to make curative medicines that promise profits over a long period.
Administration of immunization medicines is a matter of extreme sensitivity to both public and medical establishments. This is because vaccines are administered to people who are not sick to prevent them from catching a potential disease rather than cure them of an ailment. As such, it is difficult to actually estimate the effectiveness of a vaccine.
The costs involved in research, development and production of medicine are enormous. It takes the combined efforts of governments, charity organizations and individual philanthropists to fund the process. Sometimes, the cost of producing a vaccine is not justifiable and the manufacturers may incur colossal losses.
The research process is also inhibited by some challenges. Since the process is done by many specialists and scientists from all over the world, there is rampant duplication of effort. In addition, the research jobs are strenuous to all parties involved as it means spending many hours in the laboratory. For an effective drug to be created, it might take up to three years of study.
In some developed nations, there is a peculiar problem whereby some members of society refuse to take collective medicine. Such fellows cite religious, cultural and personal beliefs as reason not to take immunization drugs. This directly compromises the whole research and development process since the pathogens still have an entry point into the society.
Legal obstacles also face successful administration of immunization medicines in some industrialized nations. The application procedure to administer a vaccine is highly bureaucratic and takes a long period before acceptance. In addition, there is a high risk of litigation in countries with elaborate judicial structures. In the United States, manufacturers are always faced by the risk of getting sued for personal injury resulting from side effects of using the medication. The only way to avoid litigation is to take maximum care during vaccine development.
One of the greatest obstacles to successful launch of immunization as a preventive mechanism against occurrence of diseases in the lack of manufacturing enterprises that are willing to engage in production. Manufacturers in the United States avoid production of vaccines since these medicines are difficult to produce. There is a pressing lack of raw materials, infrastructure and man power used in production of vaccines. Furthermore, manufacturing giants are not interested in producing preventive medicines that extinguish diseases. The manufacturers prefer to make curative medicines that promise profits over a long period.
Administration of immunization medicines is a matter of extreme sensitivity to both public and medical establishments. This is because vaccines are administered to people who are not sick to prevent them from catching a potential disease rather than cure them of an ailment. As such, it is difficult to actually estimate the effectiveness of a vaccine.
The costs involved in research, development and production of medicine are enormous. It takes the combined efforts of governments, charity organizations and individual philanthropists to fund the process. Sometimes, the cost of producing a vaccine is not justifiable and the manufacturers may incur colossal losses.
The research process is also inhibited by some challenges. Since the process is done by many specialists and scientists from all over the world, there is rampant duplication of effort. In addition, the research jobs are strenuous to all parties involved as it means spending many hours in the laboratory. For an effective drug to be created, it might take up to three years of study.
In some developed nations, there is a peculiar problem whereby some members of society refuse to take collective medicine. Such fellows cite religious, cultural and personal beliefs as reason not to take immunization drugs. This directly compromises the whole research and development process since the pathogens still have an entry point into the society.
Legal obstacles also face successful administration of immunization medicines in some industrialized nations. The application procedure to administer a vaccine is highly bureaucratic and takes a long period before acceptance. In addition, there is a high risk of litigation in countries with elaborate judicial structures. In the United States, manufacturers are always faced by the risk of getting sued for personal injury resulting from side effects of using the medication. The only way to avoid litigation is to take maximum care during vaccine development.
About the Author:
Lucilla Eiche enjoys writing about vaccines and cutting edge scientific research. To get further details about vaccine development impediments, or to find out regulatory consulting experts, please visit the Benchmark Biolabs website today.